Cargando…

Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients

PURPOSE: We aimed to investigate the longitudinal changes in bone metabolic markers and bone mineral density (BMD) after starting or switching from bisphosphonate (BP) to romosozumab (ROMO) or denosumab (DENO) therapies over 12 months and to determine predictors that establish associations with chan...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Tomohiro, Arita, Kosuke, Murota, Eihiro, Hiratsuka, Shigeto, Fujita, Ryo, Ishizu, Hotaka, Asano, Tsuyoshi, Takahashi, Daisuke, Takahata, Masahiko, Iwasaki, Norimasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042469/
https://www.ncbi.nlm.nih.gov/pubmed/33847831
http://dx.doi.org/10.1007/s00774-021-01226-1
_version_ 1783678135270637568
author Shimizu, Tomohiro
Arita, Kosuke
Murota, Eihiro
Hiratsuka, Shigeto
Fujita, Ryo
Ishizu, Hotaka
Asano, Tsuyoshi
Takahashi, Daisuke
Takahata, Masahiko
Iwasaki, Norimasa
author_facet Shimizu, Tomohiro
Arita, Kosuke
Murota, Eihiro
Hiratsuka, Shigeto
Fujita, Ryo
Ishizu, Hotaka
Asano, Tsuyoshi
Takahashi, Daisuke
Takahata, Masahiko
Iwasaki, Norimasa
author_sort Shimizu, Tomohiro
collection PubMed
description PURPOSE: We aimed to investigate the longitudinal changes in bone metabolic markers and bone mineral density (BMD) after starting or switching from bisphosphonate (BP) to romosozumab (ROMO) or denosumab (DENO) therapies over 12 months and to determine predictors that establish associations with changes in BMD among the patients received the ROMO therapy. METHODS: Postmenopausal osteoporosis patients with a high risk of fracture—154 in total—were recruited; their therapies were switched to ROMO or DENO from BP/naïve or vitamin D (ND) (ND-ROMO: 43, BP-ROMO: 38, ND-DENO: 38, and BP-DENO: 35). Longitudinal changes in bone metabolic markers and BMD were evaluated. RESULTS: ROMO groups showed significant increases in BMD of the lumbar spine at 6 and 12 months and femoral neck at 12 months compared to the DENO groups. Although BP-ROMO showed significant increase in the lumbar spine BMD compared to BP-DENO, there were no significant differences in femoral neck and total hip BMDs between BP-ROMO and BP-DENO. Among the ROMO groups, % changes of BMD from baseline to 12 months were associated with bone metabolic markers at baseline and changes in TRACP-5b from baseline to 3 months. CONCLUSIONS: ROMO continuously increased BMD for 12 months and performed better than DENO. On the other hand, effects of ROMO switched from BP on BMD of femoral neck and total hip were almost same with DENO. Bone metabolic markers at baseline and changes in TRACP-5b from baseline to 3 months may predict the efficacy of ROMO after 12 months of administration.
format Online
Article
Text
id pubmed-8042469
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Singapore
record_format MEDLINE/PubMed
spelling pubmed-80424692021-04-13 Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients Shimizu, Tomohiro Arita, Kosuke Murota, Eihiro Hiratsuka, Shigeto Fujita, Ryo Ishizu, Hotaka Asano, Tsuyoshi Takahashi, Daisuke Takahata, Masahiko Iwasaki, Norimasa J Bone Miner Metab Original Article PURPOSE: We aimed to investigate the longitudinal changes in bone metabolic markers and bone mineral density (BMD) after starting or switching from bisphosphonate (BP) to romosozumab (ROMO) or denosumab (DENO) therapies over 12 months and to determine predictors that establish associations with changes in BMD among the patients received the ROMO therapy. METHODS: Postmenopausal osteoporosis patients with a high risk of fracture—154 in total—were recruited; their therapies were switched to ROMO or DENO from BP/naïve or vitamin D (ND) (ND-ROMO: 43, BP-ROMO: 38, ND-DENO: 38, and BP-DENO: 35). Longitudinal changes in bone metabolic markers and BMD were evaluated. RESULTS: ROMO groups showed significant increases in BMD of the lumbar spine at 6 and 12 months and femoral neck at 12 months compared to the DENO groups. Although BP-ROMO showed significant increase in the lumbar spine BMD compared to BP-DENO, there were no significant differences in femoral neck and total hip BMDs between BP-ROMO and BP-DENO. Among the ROMO groups, % changes of BMD from baseline to 12 months were associated with bone metabolic markers at baseline and changes in TRACP-5b from baseline to 3 months. CONCLUSIONS: ROMO continuously increased BMD for 12 months and performed better than DENO. On the other hand, effects of ROMO switched from BP on BMD of femoral neck and total hip were almost same with DENO. Bone metabolic markers at baseline and changes in TRACP-5b from baseline to 3 months may predict the efficacy of ROMO after 12 months of administration. Springer Singapore 2021-04-13 2021 /pmc/articles/PMC8042469/ /pubmed/33847831 http://dx.doi.org/10.1007/s00774-021-01226-1 Text en © The Japanese Society Bone and Mineral Research 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
Shimizu, Tomohiro
Arita, Kosuke
Murota, Eihiro
Hiratsuka, Shigeto
Fujita, Ryo
Ishizu, Hotaka
Asano, Tsuyoshi
Takahashi, Daisuke
Takahata, Masahiko
Iwasaki, Norimasa
Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients
title Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients
title_full Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients
title_fullStr Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients
title_full_unstemmed Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients
title_short Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients
title_sort effects after starting or switching from bisphosphonate to romosozumab or denosumab in japanese postmenopausal patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042469/
https://www.ncbi.nlm.nih.gov/pubmed/33847831
http://dx.doi.org/10.1007/s00774-021-01226-1
work_keys_str_mv AT shimizutomohiro effectsafterstartingorswitchingfrombisphosphonatetoromosozumabordenosumabinjapanesepostmenopausalpatients
AT aritakosuke effectsafterstartingorswitchingfrombisphosphonatetoromosozumabordenosumabinjapanesepostmenopausalpatients
AT murotaeihiro effectsafterstartingorswitchingfrombisphosphonatetoromosozumabordenosumabinjapanesepostmenopausalpatients
AT hiratsukashigeto effectsafterstartingorswitchingfrombisphosphonatetoromosozumabordenosumabinjapanesepostmenopausalpatients
AT fujitaryo effectsafterstartingorswitchingfrombisphosphonatetoromosozumabordenosumabinjapanesepostmenopausalpatients
AT ishizuhotaka effectsafterstartingorswitchingfrombisphosphonatetoromosozumabordenosumabinjapanesepostmenopausalpatients
AT asanotsuyoshi effectsafterstartingorswitchingfrombisphosphonatetoromosozumabordenosumabinjapanesepostmenopausalpatients
AT takahashidaisuke effectsafterstartingorswitchingfrombisphosphonatetoromosozumabordenosumabinjapanesepostmenopausalpatients
AT takahatamasahiko effectsafterstartingorswitchingfrombisphosphonatetoromosozumabordenosumabinjapanesepostmenopausalpatients
AT iwasakinorimasa effectsafterstartingorswitchingfrombisphosphonatetoromosozumabordenosumabinjapanesepostmenopausalpatients